When the White House announced tariffs in April on certain patented pharmaceutical products and the active ingredients used to make them, many employer plan sponsors asked the same question: Will this drive up pharmacy costs?
The answer is possibly, but likely only for a narrow slice of high-cost branded drugs, not pharmacy spend broadly or immediately.
These tariffs are aimed at pharmaceutical manufacturers, not employers. That distinction matters. Any impact on employer-sponsored health plans will depend on how manufacturers respond and how pharmacy benefit managers, or PBMs, translate those decisions into pricing, rebates, coverage decisions, and reporting.
For many employers, this may not result in any meaningful near-term change. The main value right now is understanding whether your plan relies heavily on the kinds of drugs most likely to be affected. It’s a policy development worth watching because a relatively small number of high-cost drugs already account for a disproportionate share of pharmacy spend. If manufacturers change pricing, sourcing, or supply for those products, some employer plans could see an impact.
More practical insight will emerge as manufacturers and PBMs begin to respond, but employers don’t need to wait for that to understand whether this issue is likely to matter for their plans.
What Changed
The administration’s tariff action applies to certain patented pharmaceutical products and some active pharmaceutical ingredients, with implementation beginning July 31 for large manufacturers and September 29 for smaller manufacturers. Generics and biosimilars aren’t included at this time. The policy also appears to allow for variation in how the tariffs apply across products and manufacturers, which is one reason broad disruption isn’t the base case.
The policy follows a Section 232 national security investigation, which places it in the context of national security and supply chain strategy, not just drug pricing. In practical terms, it’s designed to influence where certain drugs are manufactured and how manufacturers think about pricing in the US market.
That’s an important distinction for employers. This isn’t a direct employer cost policy. It’s a manufacturer-facing policy that could create downstream effects depending on how the market responds.
Why This Matters for Employer Pharmacy Spend
For employer plans, the potential issue is less about everyday prescriptions and more about a narrower group of high-cost branded drugs.
Current market data continue to show that specialty medications account for roughly half of total drug spending, even though they make up only a small share of overall prescriptions. At the same time, specialty therapies continue to drive a growing share of plan cost and pharmacy trend. That concentration is what makes this policy relevant.
If a manufacturer changes price, rebate strategy, or supply for one or two high-cost branded drugs with limited alternatives, the financial effect can be meaningful even if most other prescriptions are unaffected.
This is why the question isn’t whether all pharmacy costs are about to rise. They aren’t. The more useful question is whether the drugs that drive your plan’s spend are in the segment of the market most likely to be affected.
What Employers Should Realistically Expect
At this stage, the most likely near-term outcome is selective variability.
Manufacturers have several options. They can absorb tariff-related costs, pass through some portion of them, lower US prices for certain products, or make longer-term changes to sourcing and production. Those decisions are unlikely to be uniform across the market. They’ll vary by manufacturer, by product, and by competitive position. What remains unclear is which approach individual manufacturers will choose and whether those decisions will be limited to specific products or applied more broadly across branded portfolios.
For employers, any impact is most likely to show up in a few specific ways:
- Net cost changes on a small number of drugs. If a manufacturer changes pricing on a high-cost branded product, plan cost could shift directly or indirectly through rebate performance and contract guarantees.
- Coverage or prior authorization changes. If the economics of a product shift, PBMs may revisit which drugs are preferred or covered, prior authorization criteria, or alternative therapy strategies.
- Timing mismatches. The tariff effective dates don’t align neatly with most employer plan years. If manufacturers or PBMs react mid-year, employers may see changes outside of renewal season, which makes them harder to forecast and easier to miss.
Even when changes are limited to a small number of products, they can still matter if they affect budget assumptions, pharmacy trend expectations, or mid-year reporting.
Employers should also keep in mind that PBM contract structure can shape how clearly these changes appear in plan reporting. In more transparent arrangements, manufacturer pricing changes may be easier to trace. In more traditional or bundled models, the impact may be harder to isolate because pricing and rebate mechanics are less visible.
Any near-term effects are also more likely to show up in pricing, rebate performance, or coverage management than in meaningful shifts in where products are manufactured, which would take longer to materialize.
What This Could Mean for Employees and Members
For most plan members, there’s unlikely to be any immediate or noticeable change. Most prescriptions are generic, and this policy is currently focused on certain patented branded products and ingredients.
Where members could feel the impact is in a smaller number of high-cost drugs, particularly if manufacturer decisions lead PBMs to adjust:
- Which drugs are preferred or covered
- Prior authorization requirements
- Preferred alternatives
- Member cost sharing for certain products
In some cases, that could affect out-of-pocket cost, access pathways, or the need for additional communication and support during a transition.
For HR and benefits leaders, that’s another reason visibility matters. Even when the financial impact is limited to a small number of drugs, the employee experience can still matter if those therapies are clinically important or used by members with complex conditions.
What Matters for Employers Now
For most employers, the right move today isn’t to change plan design. It’s to confirm whether any top-spend drugs could be affected and make sure your PBM can explain how those changes would appear in your plan.
Here’s where we’re advising clients to focus:
- Understand whether your pharmacy spend is concentrated in a small number of high-cost branded drugs. A targeted review of top spend drivers can help determine whether this policy is likely to matter for your plan.
- Clarify how your PBM would handle manufacturer-driven pricing changes. This is a good time to revisit how net cost changes appear under your contract, how quickly they’re reflected in reporting, and whether rebate guarantees could be affected if pricing or utilization shifts mid-year.
- Pay closer attention to manufacturer and PBM communications over the next several months. The clearest early signals will likely come from manufacturer decisions and PBM updates, not from additional headlines about the policy itself.
- Be prepared for selective change, not broad disruption. If this policy affects employer-sponsored plans, it’s more likely to do so through a handful of products than through the overall pharmacy benefit.
Questions Worth Raising With Your PBM
Employers don’t need to assume disruption to ask better questions. A few practical questions can help clarify whether this is relevant to your plan:
- Which of our top-spend drugs are branded, single-source, or have limited alternatives?
- Are any of those products in categories that appear more likely to be affected based on what’s known today?
- If a manufacturer changes price, how would that affect our net cost under the current contract?
- How quickly would we see that reflected in reporting?
- If the economics of a product change materially, how would you approach coverage, preferred products, or utilization management changes?
- If a product’s coverage or utilization rules change, how would member disruption be minimized and communicated?
These are reasonable oversight questions. They help employers understand how market changes would flow through the pharmacy benefit without assuming that disruption is inevitable.
The Bottom Line
The new pharmaceutical tariffs are important, but they’re still one step removed from direct employer impact.
This is a manufacturer-focused policy intended to influence pricing and supply chain strategy. The real question for employer-sponsored plans is how manufacturers respond and how PBMs react to those decisions. For most employers, that means the near-term risk isn’t broad-based cost inflation. It’s selective movement in a relatively small number of high-cost drugs that already matter to plan performance.
For HR and benefits leaders, the right approach is straightforward: stay informed, understand which drugs drive your pharmacy spend, and make sure your PBM can clearly explain how any changes would show up in your pharmacy benefit.
Employers will be best positioned if they focus on the handful of drugs that matter most, stay close to their PBM, and avoid reacting to the headline alone.
That isn’t a call for immediate plan changes. It’s a call for good visibility and sound oversight.
Looking for Clearer Insight Into Your Pharmacy Strategy?
Pharmacy costs are often driven by a small number of high‑impact decisions. Reach out to learn how Sequoia helps employers evaluate spend drivers, PBM dynamics, and member impact with greater clarity.
Last Updated:
